(Q53609143)

16 May 2018

title

Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. (English)

1 reference

16 May 2018

author name string

Jönsson B

series ordinal

1

1 reference

16 May 2018

Weinstein MC

series ordinal

2

1 reference

16 May 2018

publication date

1 January 1997

1 reference

16 May 2018

International Journal of Technology Assessment in Health Care

published in

1 reference

16 May 2018

volume

13

1 reference

16 May 2018

issue

1

1 reference

16 May 2018

page(s)

49-58

1 reference

16 May 2018

Cost-effectiveness of thrombolysis--a randomized study of intravenous rt-PA in suspected myocardial infarction

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

The friction cost method for measuring indirect costs of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

7 January 2021

Cost-effectiveness of interventions to prevent or treat coronary heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

7 January 2021

Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

7 January 2021

Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

7 January 2021

Economic analysis in randomized control trials

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

7 January 2021

Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

7 January 2021

Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

7 January 2021

Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300010229

7 January 2021

10.1017/S0266462300010229

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018